Now available ROLVEDON™

ROLVEDON™ (eflapegrastim-xnst) is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia.

Please see full prescribing information here.